Determination of flumazenil in serum by liquid chromatography-mass spectrometry: Application to kinetics study in acute diazepam overdose

Snežana B Djordjević; Jasmina Jović-Stošoć; Vesna Kilibarda; Zoran Šegrt; Nataša Perković-Vukčević

doi:10.2298/7418

Snežana B Djordjević National Poison Control Center, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Jasmina Jović-Stošoć National Poison Control Center, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Vesna Kilibarda National Poison Control Center, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Zoran Šegrt Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Nataša Perković-Vukčević National Poison Control Center, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia

DOI: https://doi.org/10.2298/7418

Keywords: diazepam, poisoning, flumazenil, aminophylline, chromatography, liquid, mass spectrometry,

Abstract

Backgound/Aim. Flumazenil is benzodiazepine receptor antagonist. It has been studied for a various indications, including reversal of sedation after surgery or diagnostic procedures, awakening of comatose patients in benzodiazepine overdose, or for symptomatic treatment of hepatic encephalopathy. Some drugs, like theophylline, may prolong its elimination half-life. Considering the long half-life of diazepam and its metabolites, concomitant use of theophylline may reduce the need for repeated dosing of flumazenil in patients with acute diazepam poisoning. The aim of this study was to introduce a reliable and accurate method for determining the concentration of flumazenil after therapeutic application in patients with acute poisoning, and using that method to assess whether the kinetics of flumazenil change in the presence of aminophylline (combination of theophylline and ethylenediamine in a 2 : 1 ratio) applied as concomitant therapy. Methods. Blood samples from patients with acute diazepam poisoning that received flumazenil at the dose of 0.5 mg, or the same dose with 3 mg/kg of body weight of aminophylline, were collected 1, 3, 10, 30, 60, 120 and 240 min after its intravenous administration. Samples were prepared by solid-phase extraction on Oasis HLB cartridges with ethylacetate as extracting agens. Flumazenil was determined by liquid chromatography with mass spectrometry (LC-MS) in single ion monitoring mode at m/z 304. Separation of flumazenil from matrix compound was performed on Lichrospher RP-8 column using the mixture of acidic acetonitrile and 20 mM of ammonium acetate in water (55 : 45) as a mobile phase. Results. The applied analitycal method showed excellent recovery (94.65%). The obtained extracts were much cleaner than the extracts obtained by the same extractant in the process of liquid-liquid extraction. The limit of detection of the LC-MS method described in this paper was 0.5 ng/mL and the limit of quantitation was 1 ng/mL. In the patients treated with both flumazenil and aminophylline, the elimination constant for flumazenil was significantly lower and the elimination half-life was longer (p < 0.05) in comparison with the same parameters in the patients who received flumazenil alone. Conclusion. The applied LC-MS method for the determination of flumazenil in serum samples of patients with acute diazepam poisoning is rapid, sensitive, precise and specific. Concomitant use with theophylline significantly prolonged elimination of flumazenil during the treatment of acute poisonings with diazepam.

References

Anexate (Flumazenil) product monograph. Basle, Switzerland: F. Hoffmann-La Roche & Co. Limited Company; 1987. [published 2008 December 30]. Available from: http://rochecanada.com/fmfiles/re7234008/Research/ClinicalTrialsForms/Products/Consumer information/ MonographsandPublic Adviso-ries/Anexate/anexateJune3pmE.pdf.

Votey SR, Bosse GM, Bayer MJ, Hoffman JR. Flumazenil: a new benzodiazepine antagonist. Ann Emerg Med 1991; 20(2): 181−8.

Whitwam JG, Amrein R. Pharmacology of flumazenil. Acta Anaesthesiol Scand Suppl 1995; 108: 3−14.

Wille RT, Chaffee BW, Ryan ML, Elta GH, Walter V, Barnett JL. Pharmacoeconomic evaluation of flumazenil for routine outpatient EGD. Gastrointest Endosc 2000; 51(3): 282−7.

Krisanda TJ. Flumazenil: an antidote for benzodiazepine tox-icity. Am Fam Physician 1993; 47(4): 891−5.

Weinbroum A, Rudick V, Sorkine P, Nevo Y, Halpern P, Geller E, et al. Use of flumazenil in the treatment of drug overdose: a double-blind and open clinical study in 110 patients. Crit Care Med 1996; 24(2): 199−206.

Als-Nielsen B, Kjaergard LL, Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 2001; (4): CD002798.

Hoffman EJ, Warren EW. Flumazenil: a benzodiazepine anta-gonist. Clin Pharm 1993; 12(9): 641−56.

Mégarbane B, Buisine A, Jacobs F, Résière D, Chevillard L, Vicaut E, et al. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. J Subst Abuse Treat 2010; 38(4): 403−7.

Woolf AD, Erdman AR, Nelson LS, Caravati E, Cobaugh DJ, Booze LL, et al. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007; 45(3): 203−33.

Lopez A, Rebollo J. Benzodiazepine withdrawal syndrome after a benzodiazepine antagonist. Crit Care Med 1990; 18(12): 1480−1.

Marchant B, Wray R, Leach A, Nama M. Flumazenil causing convulsions and ventricular tachycardia. BMJ 1989; 299(6703): 860.

Thomson JS, Donald C, Lewin K. Use of Flumazenil in Benzodia-zepine overdose. Emerg Med J 2006; 23(2): 162.

Klotz U, Duka T, Dorow R, Doenicke A. Flunitrazepam and lor-metazepam do not affect the pharmacokinetics of the benzo-diazepine antagonist Ro 15-1788. Br J Clin Pharmacol 1985; 19(1): 95−8.

Bonfiglio MF, Fisher-Katz LE, Saltis LM, Traeger SM, Martin BR, Nackes NA, et al. A pilot pharmacokinetic-pharmacodynamic study of benzodiazepine antagonism by flumazenil and ami-nophylline. Pharmacotherapy 1996; 16(6): 1166−72.

Scheepers LD, Montgomery CJ, Kinahan AM, Dunn GS, Bourne RA, McCormack JP. Plasma concentration of flumazenil following intranasal administration in children. Can J Anaesth 2000; 47(2): 120−4.

Bun H, Duplan V, Crevat-Pisano P, Llurens M, Durand A. Rapid determination of the benzodiazepine antagonist flumazenil, Ro 15-1788, by high performance liquid chromatography. Biomed Chromatogr 1989; 3(6): 269−71.

Zedkova L, Rauw GA, Baker GB, Coupland NJ. A rapid high-pressure liquid chromatographic procedure for determination of flumazenil in plasma. J Pharmacol Toxicol Methods 2001; 46(1): 57−60.

Vletter AA, Burm AG, Breimer LT, Spierdijk J. High-performance liquid chromatographic assay to determine mida-zolam and flumazenil simultaneously in human plasma. J Chromatogr 1990; 530(1): 177−85.

Chan K, Jones RD. Simultaneous determination of flumazenil, midazolam and metabolites in human biological fluids by liq-uid chromatography. J Chromatogr 1993; 619(1): 154−60.

Lavén M, Appel L, Moulder R, Tyrefors N, Markides K, Långström B. Determination of flumazenil in human plasma by liquid chromatography-electrospray ionisation tandem mass spec-trometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 808(2): 221−7.

Kanazawa H, Nagata Y, Matsushima Y, Takai N, Uchiyama H, Ni-shimura R, et al. Liquid chromatography-mass spectrometry for the determination of medetomidine and other anaesthetics in plasma. J Chromatogr 1993; 631(1−2): 215−20.

Lavén M, Markides K, Långström B. Analysis of microsomal me-tabolic stability using high-flow-rate extraction coupled to ca-pillary liquid chromatography-mass spectrometry. J Chroma-togr B Analyt Technol Biomed Life Sci 2004; 806(2): 119−26.

Djordjevic S, Kovacevic I, Miljkovic B, Vuksanovic J, Pokrajac M. Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plas-ma: application to clinical study. Farmaco 2005; 60(4): 345−9.

Kratzsch C, Tenberken O, Peters FT, Weber AA, Kraemer T, Maurer HH. Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatogra-phy/mass spectrometry with atmospheric pressure chemical ionization. J Mass Spectrom 2004; 39(8): 856−72.

Song D, Khaykis V, Kohlhof K. Determination of flumazenil in plasma by gas chromatography-negative ion chemical ioniza-tion mass spectrometry. J Chromatogr B Biomed Appl 1995; 663(2): 263−73.

Fisher LE, Perch S, Bonfiglio MF, Geers SM. Simultaneous deter-mination of midazolam and flumazenil concentrations in hu-man plasma by gas chromatography. J Chromatogr B, Biomed Appl 1995; 665(1): 217−21.

Najjar TA, Al-Hassan MI, Khan RM. Theophylline inhibits the elimination of flumazenil in rabbits. Int J Pharm 1993; 98(1−3): 51−5.

Klotz U, Kanto J. Pharmacokinetics and Clinical Use of Fluma-zenil (Ro 15-1788). Clin Pharmacokin 1988; 14(1): 1−12.

Kleingeist B, Bocker R, Geisslinger G, Brugge R. Isolation and pharmacological characterization of microsomal human liver flumazenil carboxylesterase. J Pharm Pharmaceut Sci 1998; 1(1): 38−46.

Dahaba AA, Bornemann H, Rehak PH, Wang G, Wu XM, Metzler H. Effect of flumazenil on bispectral index monitoring in un-premedicated patients. Anesthesiology 2009; 110(5): 1036−40.

Kim YJ, Lee H, Kim CH, Lee GY, Baik HJ, Han JI. Effect of flumazenil on recovery from anesthesia and the bispectral in-dex after sevoflurane/fentanyl general anesthesia in unpreme-dicated patients. Korean J Anesthesiol 2012; 62(1): 19−23.

Turan A, Memiş D, Karamanlýodthlu B, Pamukçu Z, Süt N. Effect of aminophylline on bispectral index. Acta Anaesthesiol Scand 2004; 48(4): 408−11.

Kim DW, Joo JD, In JH, Jeon YS, Jung HS, Jeon KB, Choi JW. Comparison of the recovery and respiratory effects of amino-phylline and doxapram following total intravenous anesthesia with propofol and remifentanil. J Clin Anesth 2013;25(3):173−6.